OBJECTIVE: A dose-dependent increase in risk of sudden cardiac death for the antipsychotic drug risperidone was reported. However, few reports have so far addressed QT prolongation associated with the use of risperidone or its major active metabolite, which is also used as a separate antipsychotic drug, paliperidone. METHODS: The present study evaluated associations between risperidone metabolism and QT interval in 61 psychiatric patients who had been receiving risperidone for ≥4 weeks at an average dosage of 4.7 mg/day. Plasma risperidone and paliperidone levels were measured and electrocardiographic measurements were also obtained. RESULTS: There was no correlation between risperidone dosage and QTc or plasma risperidone levels and QTc. However, there was a significant positive correlation between plasma paliperidone levels and QTc (r = 0.361; p = 0.004). There was no correlation between age and dose-corrected plasma risperidone levels or between age and QTc. There was a significant positive correlation between age and dose-corrected plasma paliperidone levels (r = 0.290; p = 0.023). CONCLUSION: Clinically, paliperidone is considered to play a more important role in QT prolongation than risperidone.
OBJECTIVE: A dose-dependent increase in risk of sudden cardiac death for the antipsychotic drug risperidone was reported. However, few reports have so far addressed QT prolongation associated with the use of risperidone or its major active metabolite, which is also used as a separate antipsychotic drug, paliperidone. METHODS: The present study evaluated associations between risperidone metabolism and QT interval in 61 psychiatricpatients who had been receiving risperidone for ≥4 weeks at an average dosage of 4.7 mg/day. Plasma risperidone and paliperidone levels were measured and electrocardiographic measurements were also obtained. RESULTS: There was no correlation between risperidone dosage and QTc or plasma risperidone levels and QTc. However, there was a significant positive correlation between plasma paliperidone levels and QTc (r = 0.361; p = 0.004). There was no correlation between age and dose-corrected plasma risperidone levels or between age and QTc. There was a significant positive correlation between age and dose-corrected plasma paliperidone levels (r = 0.290; p = 0.023). CONCLUSION: Clinically, paliperidone is considered to play a more important role in QT prolongation than risperidone.
Authors: Maciej Jakub Lazarczyk; Zahir A Bhuiyan; Nicolas Perrin; Panteleimon Giannakopoulos Journal: BMC Psychiatry Date: 2012-12-05 Impact factor: 3.630
Authors: Bradley J Ridder; Derek J Leishman; Matthew Bridgland-Taylor; Mohammadreza Samieegohar; Xiaomei Han; Wendy W Wu; Aaron Randolph; Phu Tran; Jiansong Sheng; Timm Danker; Anders Lindqvist; Daniel Konrad; Simon Hebeisen; Liudmila Polonchuk; Evgenia Gissinger; Muthukrishnan Renganathan; Bryan Koci; Haiyang Wei; Jingsong Fan; Paul Levesque; Jae Kwagh; John Imredy; Jin Zhai; Marc Rogers; Edward Humphries; Robert Kirby; Sonja Stoelzle-Feix; Nina Brinkwirth; Maria Giustina Rotordam; Nadine Becker; Søren Friis; Markus Rapedius; Tom A Goetze; Tim Strassmaier; George Okeyo; James Kramer; Yuri Kuryshev; Caiyun Wu; Herbert Himmel; Gary R Mirams; David G Strauss; Rémi Bardenet; Zhihua Li Journal: Toxicol Appl Pharmacol Date: 2020-03-21 Impact factor: 4.219
Authors: Xin Zhou; Yusheng Qu; Elisa Passini; Alfonso Bueno-Orovio; Yang Liu; Hugo M Vargas; Blanca Rodriguez Journal: Front Pharmacol Date: 2020-01-30 Impact factor: 5.810